secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2022-12-14T23:59:59+00:00
Accession:  0001193125-22-303934
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm reports Phase 1 selinexor+ruxolitinib data: 92% spleen response at week 24 in myelofibrosis
--------------------------------------------------------------------------------

- At week 24, 92% (11/12) evaluable patients achieved ≥35% spleen volume reduction (SVR35).
- Median spleen volume reduction of 45% at week 12 and 49% at week 24.
- 67% (4/6) evaluable patients achieved ≥50% symptom reduction (TSS50) at week 24.
- 57% (13/23) transfusion-independent patients maintained or improved hemoglobin levels.
- Common grade 3-4 AEs: anemia (37%) and thrombocytopenia (21%), both reversible.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312522303934/0001193125-22-303934-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312522303934/d426577d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-303934

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer